Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments Treatment...

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma – Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong relationship between IRF4 and p300 in Multiple Myeloma – – Poster presentation to take place on...